These results from clinical samples support our in vitro data showing that the CCL2–CCR2 axis-induced CCL22 triggered CCR4 production and that both the CCL2–CCR2 and CCL22–CCR4 axes contributed to prostate cancer progression. Here, CCR4 is linked to prostate cancer.